AstraZeneca PLC Directorate Change (6332O)
November 09 2016 - 1:01AM
UK Regulatory
TIDMAZN
RNS Number : 6332O
AstraZeneca PLC
09 November 2016
9 November 2016 07:00
CHANGE TO ASTRAZENECA BOARD OF DIRECTORS
AstraZeneca today announced that Jean-Philippe Courtois, a
Non-Executive Director, will step down from the Board of
AstraZeneca PLC and as a member of the Company's Audit Committee
with effect from 1 December 2016.
Mr Courtois was appointed as a Non-Executive Director of
AstraZeneca in 2008. The Board's Nomination and Governance
Committee started succession planning work in February this year,
in anticipation of him reaching nine years' tenure in 2017. Mr
Courtois has recently taken on new responsibilities as Executive
Vice President and President, Microsoft Global Sales, Marketing and
Operations.
Leif Johansson, AstraZeneca Chairman, said: "On behalf of the
Board, I would like to express my gratitude for Jean-Philippe's
contribution to our work and that of the Audit Committee. I speak
for all my colleagues in saying that we will miss his business
acumen, extensive experience of the global technology industry,
common sense and collegiality. We wish him all the best for his
future endeavours."
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com and follow us on Twitter
@AstraZeneca.
Media Enquiries
Neil Burrows UK/Global +44 203 749 5637
Vanessa Rhodes UK/Global +44 203 749 5736
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, neuroscience & infection +44 203 749 5711
US toll free +1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
-ENDS-
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAFSFFDAFMSEDF
(END) Dow Jones Newswires
November 09, 2016 02:01 ET (07:01 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025
